{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T21:47:40Z","timestamp":1792705660410,"version":"4.5.0"},"reference-count":14,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,3,20]],"date-time":"2026-03-20T00:00:00Z","timestamp":1773964800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Urology"],"published-print":{"date-parts":[[2026,8]]},"DOI":"10.1016\/j.eururo.2026.03.005","type":"journal-article","created":{"date-parts":[[2026,4,3]],"date-time":"2026-04-03T03:33:51Z","timestamp":1775187231000},"page":"108-113","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"title":["KIM-1 in Advanced Papillary and Clear Cell Renal Cell Carcinoma"],"prefix":"10.1016","volume":"90","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9769-5766","authenticated-orcid":false,"given":"Sara","family":"Coca Membribes","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenxin","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cristina","family":"Su\u00e1rez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Poulam M.","family":"Patel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James","family":"Larkin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bego\u00f1a P.","family":"Valderrama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charles","family":"Mein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charlotte","family":"Ackerman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Powles","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.eururo.2026.03.005_b0005","doi-asserted-by":"crossref","first-page":"2691","DOI":"10.1200\/JCO.23.00699","article-title":"Plasma kidney injury molecule-1 for preoperative prediction of renal cell carcinoma versus benign renal masses, and association with clinical outcomes","volume":"42","author":"Xu","year":"2024","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.eururo.2026.03.005_b0010","doi-asserted-by":"crossref","first-page":"1525","DOI":"10.1016\/j.annonc.2025.08.007","article-title":"Circulating kidney injury molecule-1 (KIM-1) and association with outcome to adjuvant immunotherapy in renal cell carcinoma","volume":"36","author":"Rini","year":"2025","journal-title":"Ann Oncol"},{"key":"10.1016\/j.eururo.2026.03.005_b0015","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1038\/ki.2012.11","article-title":"Kim-1\/Tim-1 and immune cells: shifting sands","volume":"81","author":"Ichimura","year":"2012","journal-title":"Kidney Int"},{"key":"10.1016\/j.eururo.2026.03.005_b0020","doi-asserted-by":"crossref","first-page":"1767","DOI":"10.1056\/NEJMoa2212851","article-title":"Cabozantinib plus Nivolumab and Ipilimumab in renal-cell carcinoma","volume":"388","author":"Choueiri","year":"2023","journal-title":"N Engl J Med"},{"key":"10.1016\/j.eururo.2026.03.005_b0025","doi-asserted-by":"crossref","first-page":"1277","DOI":"10.1056\/NEJMoa1712126","article-title":"Nivolumab plus Ipilimumab versus Sunitinib in advanced renal-cell carcinoma","volume":"378","author":"Motzer","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.eururo.2026.03.005_b0030","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1056\/NEJMoa2026982","article-title":"Nivolumab plus Cabozantinib versus Sunitinib for advanced renal-cell carcinoma","volume":"384","author":"Choueiri","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.eururo.2026.03.005_b0035","doi-asserted-by":"crossref","first-page":"1116","DOI":"10.1056\/NEJMoa1816714","article-title":"Pembrolizumab plus Axitinib versus Sunitinib for advanced renal-cell carcinoma","volume":"380","author":"Rini","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.eururo.2026.03.005_b0040","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1016\/j.annonc.2024.12.003","article-title":"Biomarker analyses from the phase III randomized CLEAR trial: lenvatinib plus pembrolizumab versus sunitinib in advanced renal cell carcinoma","volume":"36","author":"Motzer","year":"2025","journal-title":"Ann Oncol"},{"key":"10.1016\/j.eururo.2026.03.005_b0045","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2021-004316","article-title":"Biomarker analysis from CheckMate 214: Nivolumab plus ipilimumab versus sunitinib in renal cell carcinoma","volume":"10","author":"Motzer","year":"2022","journal-title":"J Immunother Cancer"},{"key":"10.1016\/j.eururo.2026.03.005_b0050","doi-asserted-by":"crossref","first-page":"3397","DOI":"10.1158\/1078-0432.CCR-21-0025","article-title":"Plasma KIM-1 is associated with recurrence risk after nephrectomy for localized renal cell carcinoma: a trial of the ECOG-ACRIN research group (E2805)","volume":"27","author":"Xu","year":"2021","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.eururo.2026.03.005_b0055","doi-asserted-by":"crossref","first-page":"2493","DOI":"10.1200\/JCO.22.01414","article-title":"Phase II study investigating the safety and efficacy of Savolitinib and Durvalumab in metastatic papillary renal cancer (CALYPSO)","volume":"41","author":"S\u00fa Arez","year":"2023","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.eururo.2026.03.005_b0060","doi-asserted-by":"crossref","first-page":"S1398","DOI":"10.1016\/j.annonc.2025.08.3221","article-title":"2605MO Final efficacy data and biomarker analysis from the clear cell cohort of CALYPSO","volume":"36","author":"Coca Membribes","year":"2025","journal-title":"Ann Oncol"},{"key":"10.1016\/j.eururo.2026.03.005_b0065","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1200\/JCO.2025.43.5_suppl.444","article-title":"Final overall survival and new ctDNA analysis in MET-driven advanced papillary renal cancer (CALYPSO)","volume":"43","author":"Jackson-Spence","year":"2025","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.eururo.2026.03.005_b0070","doi-asserted-by":"crossref","first-page":"3645","DOI":"10.1172\/JCI46274","article-title":"Regulatory B cells are identified by expression of TIM-1 and can be induced through TIM-1 ligation to promote tolerance in mice","volume":"121","author":"Ding","year":"2011","journal-title":"J Clin Invest"}],"container-title":["European Urology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0302283826020403?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0302283826020403?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,8,4]],"date-time":"2026-08-04T23:26:22Z","timestamp":1785885982000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0302283826020403"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8]]},"references-count":14,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,8]]}},"alternative-id":["S0302283826020403"],"URL":"https:\/\/doi.org\/10.1016\/j.eururo.2026.03.005","relation":{},"ISSN":["0302-2838"],"issn-type":[{"value":"0302-2838","type":"print"}],"subject":[],"published":{"date-parts":[[2026,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"KIM-1 in Advanced Papillary and Clear Cell Renal Cell Carcinoma","name":"articletitle","label":"Article Title"},{"value":"European Urology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.eururo.2026.03.005","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author(s). Published by Elsevier B.V. on behalf of European Association of Urology.","name":"copyright","label":"Copyright"}]}}